RxDoctor Payments Data

Libero Saraceno, MD

Internal Medicine · Newark, NJNPI 1770637928

Payments from drug & device makers

$1,265in general payments, 2019–2025

Across 75 payments — averaging $16.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$230
  • AbbVie$187
  • Lilly USA, LLC$130
  • Pfizer$120
  • Bayer$92
  • Boston Scientific$84
  • plus $422 from 11 others

What the payments were for

  • Food & beverage$1,24298%
  • Education$232%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,265 in reported general payments places this provider in the 70th percentile of 4,032 internal medicine providers in New Jersey.

See all internal medicine providers in New Jersey

Medicare billing

Part B allowed, 2024
$161,413
Medicare patients
286
Services billed
3,726

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide135$253,698
JardianceEmpagliflozin120$180,709
EliquisApixaban147$180,683
MounjaroTirzepatide95$141,326
TrulicityDulaglutide66$101,152
XareltoRivaroxaban63$92,319
JanuviaSitagliptin Phosphate73$86,323
JanumetSitagliptin Phos/Metformin Hcl72$84,635
FarxigaDapagliflozin Propanediol26$35,900
TradjentaLinagliptin20$21,732
MyrbetriqMirabegron25$21,478
Trelegy ElliptaFluticasone/Umeclidin/Vilanter32$21,268
LinzessLinaclotide21$19,911
Diclofenac Sodium62$11,999
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog35$11,201

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$230$253,698135 claims
Lilly USA, LLCMounjaro, Trulicity$130$242,478161 claims
PfizerEliquis$120$180,683147 claims
MerckJanuvia, Janumet$64$170,958145 claims
Johnson & JohnsonXarelto$32$92,31963 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$23$53,51959 claims
GSKTrelegy Ellipta, Anoro Ellipta$83$30,72146 claims
AbbVieLinzess$187$19,91121 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 4,032 internal medicine providers in New Jersey.

Other internal medicine in Newark

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →